Search by Drug Name, NDC or Jcode

    Internal Navigation

    HCPCS Details

    HCPC Q5110
    Short Description Nivestym
    Long Description Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
    Pricing indicator 51
    Coverage code D
    ASC payment group code YY
    BETOS2 code O1E
    Action code N
    Type of service 1
    Effective date 2018-10-01
    Date Added 2018-10-01

    HCPCS/NDC Cross-Walk

    NDC HCPC Description Drug Name Labeler Name HCPCS Dosage PKG Size PKG QTY Bill Units Bill Units PKG
    00069029101 Q5110 Nivestym Nivestym PFIZER INC. 1 MCG 0.5 1 300 300
    00069029110 Q5110 Nivestym Nivestym PFIZER INC. 1 MCG 0.5 10 300 3000
    00069029201 Q5110 Nivestym Nivestym PFIZER INC. 1 MCG 0.8 1 480 480
    00069029210 Q5110 Nivestym Nivestym PFIZER INC. 1 MCG 0.8 10 480 4800
    00069029310 Q5110 Nivestym Nivestym PFIZER INC. 1 MCG 1 10 300 3000
    00069029410 Q5110 Nivestym Nivestym PFIZER INC. 1 MCG 1.6 10 480 4800
    The ASP crosswalks are maintained by the Division of Data Analysis and Market Based Pricing to support ASP-based Medicare Part B payments only. The crosswalks are intended to help the public (including entities that submit manufacturer ASP data and providers who bill for drugs) understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes. The crosswalks are not intended to be a comprehensive list of all drugs/NDCs available in the United States. The NDC to HCPCS Crosswalk also includes information on the NDC package size and the number of billable units (as defined by the HCPCS code descriptor). Comments on the file may be sent to [email protected].

    HCPCS Billing Calculator

    Dosage given to patient (per dose)
    HCPCS Dosage 1 MCG
    HCPCS/CPT Billing Units 1
    Total doses ordered
    Billing Units 1

    Drug Details

    • Filgrastim injection products (Granix, Neupogen, Nivestym, Releuko, Zarxio) are used to decrease the chance of infection in people who have non myeloid cancer (cancer that does not involve the bone marrow) and are receiving chemotherapy medications that may decrease the number of neutrophils (a type of blood cell needed to fight infection). Filgrastim injection products (Neupogen, Nivestym, Releuko, Zarxio) are also used to help increase the number of white blood cells, and decrease the length of time with fever in people with acute myeloid leukemia (AML; a type of cancer of the white blood cells) who are receiving treatment with chemotherapy medications. Filgrastim injection products (Neupogen, Nivestym, Releuko, Zarxio) are also used in people who are undergoing bone marrow transplants and in people who have severe chronic neutropenia (condition in which there are a low number of neutrophils in the blood). Filgrastim injection products (Neupogen, Nivestym, Zarxio) are also used to prepare the blood for leukapheresis (a treatment in which certain blood cells are removed from the body. Filgrastim injection (Neupogen) is also used to increase the chance of survival in people who have been exposed to harmful amounts of radiation, which can cause severe and life-threatening damage to your bone marrow. Filgrastim is in a class of medications called colony-stimulating factors. It works by helping the body make more neutrophils.